Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient
News
IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced. “The first immunization of ... Read more